HIGHLIGHTS
- who: Kreina Sharela Vega Cano and colleagues from the Medical Oncology Department, d`Hebron University Hospital, Barcelona, Spain have published the research work: Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends, in the Journal: Cancers 2023, 15, 51. of 16/Dec/2022
- what: A limitation of the study is that patients were not stratified according to CD16A status, with the lack of a companion diagnostic test developed to select patients with the CD16A-158F allele that might yield the most benefit from margetuximab. This trial showed an improved mPFS of 9 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.